Previous close | 1.1000 |
Open | 1.0500 |
Bid | 0.9000 |
Ask | 1.3500 |
Strike | 2.00 |
Expiry date | 2024-12-20 |
Day's range | 1.0000 - 1.0500 |
Contract range | N/A |
Volume | |
Open interest | 95 |
BOSTON, September 10, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT.
BOSTON, September 10, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the acceptance of a late-breaking abstract of the mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Meeting taking place October 16-18, 2024 in Dublin, Ireland. The presentati
BOSTON & HOUSTON, Texas, September 03, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or "LGSOC Awareness Day" on September 9, 2024.